Scientists at the University of Cambridge have developed "proactive vaccinology" technology designed to provide immunity against coronaviruses that have not yet emerged in humans. The research involves testing shots on mice to recognize pathogens currently found in bats. Critics argue this new terminology is a rebranding effort for gene therapy products that lack traditional manufacturer liability.
